New Insights in Epigenetics of Hepatocellular Carcinoma
Journal: Journal of Clinical Medicine Research DOI: 10.32629/jcmr.v6i2.4055
Abstract
Hepatocellular carcinoma (HCC) is the most common primary malignant tumor of the liver, characterized by a high mortality rate. Genetic and epigenetic abnormalities are frequently observed in HCC. Epigenetic changes, including DNA methylation, histone modifications, chromatin remodeling, and non-coding RNA expression, are significant in the development and metastasis of HCC. This summary outlines the epigenetic changes involved in the progression of HCC, as well as the epigenetic modifications associated with HCC treatment and the progress of HCC epigenetic biomarkers. Especially, the potential value of the combination therapy strategy of epigenetic alteration inhibitors with cytotoxic and immunotherapy drugs is highlighted. Epigenetic abnormalities, distinguished from genetic mutations by their inherent reversibility, have the potential to become an ideal target for small molecule drugs (epigenetic drugs) in the treatment of HCC. This study aims to offer novel insights to clinical physicians for the development of rational clinical strategies, enhancement of overall patient survival, and prediction of treatment outcomes.
Keywords
hepatocellular carcinoma,epigenetics,biomarkers,treatment
Full Text
PDF - Viewed/Downloaded: 1 TimesReferences
[1]Bray F, Laversanne M, Sung H, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024; 74: 229-263.
[2]Li Y. Modern epigenetics methods in biological research. Methods. 2021; 187: 104-113.
[3]Hernandez-Meza G, von Felden J, Gonzalez-Kozlova EE, et al. DNA Methylation Profiling of Human Hepatocarcinogenesis. Hepatology. 2021; 74: 183-199.
[4]Meunier L, Hirsch TZ, Caruso S, et al. DNA Methylation Signatures Reveal the Diversity of Processes Remodeling Hepatocellular Carcinoma Methylomes. Hepatology. 2021.
[5]Meng C, Shen X, Jiang W. Potential biomarkers of HCC based on gene expression and DNA methylation profiles. Oncol Lett. 2018; 16: 3183-3192.
[6]Fan G, Tu Y, Chen C, et al. DNA methylation biomarkers for hepatocellular carcinoma. Cancer Cell International. 2018; 18.
[7]Zheng YF, Lu X, Zhang XY, et al. The landscape of DNA methylation in hepatocellular carcinoma. J Cell Physiol. 2019; 234: 2631-2638.
[8]Dreval K, Tryndyak V, de Conti A, et al. Gene Expression and DNA Methylation Alterations During Non-alcoholic Steatohepatitis-Associated Liver Carcinogenesis. Front Genet. 2019; 10: 486.
[9]Luo B, Ma F, Liu H, et al. Cell-free DNA methylation markers for differential diagnosis of hepatocellular carcinoma. BMC Med. 2022; 20: 8.
[10]Liu A, Wu Q, Peng D, et al. A novel strategy for the diagnosis, prognosis, treatment, and chemoresistance of hepatocellular carcinoma: DNA methylation. Med Res Rev. 2020; 40: 1973-2018.
[11]Udali S, Castagna A, Corbella M, et al. Hepcidin and DNA promoter methylation in hepatocellular carcinoma. Eur J Clin Invest. 2018; 48: e12870.
[12]Wolinska E, Skrzypczak M. Epigenetic Changes Affecting the Development of Hepatocellular Carcinoma. Cancers (Basel). 2021; 13.
[13]Hlady RA, Zhao X, Pan X, et al. Genome-wide discovery and validation of diagnostic DNA methylation-based biomarkers for hepatocellular cancer detection in circulating cell free DNA. Theranostics. 2019; 9: 7239-7250.
[14]Long J, Chen P, Lin J, et al. DNA methylation-driven genes for constructing diagnostic, prognostic, and recurrence models for hepatocellular carcinoma. Theranostics. 2019; 9: 7251-7267.
[15]Zhao P, Malik S, Xing S. Epigenetic Mechanisms Involved in HCV-Induced Hepatocellular Carcinoma (HCC). Front Oncol. 2021; 11: 677926.
[16]Frederick RM, 2nd, Brandt J, Sheyn A. Drug-induced sleep endoscopy effect on intraoperative decision making in pediatric sleep surgery: A 2-year follow up. Laryngoscope Investig Otolaryngol. 2022; 7: 2112-2118.
[17]Xu Q, Hu Y, Chen S, et al. Immunological Significance of Prognostic DNA Methylation Sites in Hepatocellular Carcinoma. Front Mol Biosci. 2021; 8: 683240.
[18]Cheng J, Wei D, Ji Y, et al. Integrative analysis of DNA methylation and gene expression reveals hepatocellular carcinoma-specific diagnostic biomarkers. Genome Med. 2018; 10: 42.
[19]Li GX, Ding ZY, Wang YW, et al. Integrative analysis of DNA methylation and gene expression identify a six epigenetic driver signature for predicting prognosis in hepatocellular carcinoma. J Cell Physiol. 2019; 234: 11942-11950.
[20]Li G, Xu W, Zhang L, et al. Development and validation of a CIMP-associated prognostic model for hepatocellular carcinoma. EBioMedicine. 2019; 47: 128-141.
[2]Li Y. Modern epigenetics methods in biological research. Methods. 2021; 187: 104-113.
[3]Hernandez-Meza G, von Felden J, Gonzalez-Kozlova EE, et al. DNA Methylation Profiling of Human Hepatocarcinogenesis. Hepatology. 2021; 74: 183-199.
[4]Meunier L, Hirsch TZ, Caruso S, et al. DNA Methylation Signatures Reveal the Diversity of Processes Remodeling Hepatocellular Carcinoma Methylomes. Hepatology. 2021.
[5]Meng C, Shen X, Jiang W. Potential biomarkers of HCC based on gene expression and DNA methylation profiles. Oncol Lett. 2018; 16: 3183-3192.
[6]Fan G, Tu Y, Chen C, et al. DNA methylation biomarkers for hepatocellular carcinoma. Cancer Cell International. 2018; 18.
[7]Zheng YF, Lu X, Zhang XY, et al. The landscape of DNA methylation in hepatocellular carcinoma. J Cell Physiol. 2019; 234: 2631-2638.
[8]Dreval K, Tryndyak V, de Conti A, et al. Gene Expression and DNA Methylation Alterations During Non-alcoholic Steatohepatitis-Associated Liver Carcinogenesis. Front Genet. 2019; 10: 486.
[9]Luo B, Ma F, Liu H, et al. Cell-free DNA methylation markers for differential diagnosis of hepatocellular carcinoma. BMC Med. 2022; 20: 8.
[10]Liu A, Wu Q, Peng D, et al. A novel strategy for the diagnosis, prognosis, treatment, and chemoresistance of hepatocellular carcinoma: DNA methylation. Med Res Rev. 2020; 40: 1973-2018.
[11]Udali S, Castagna A, Corbella M, et al. Hepcidin and DNA promoter methylation in hepatocellular carcinoma. Eur J Clin Invest. 2018; 48: e12870.
[12]Wolinska E, Skrzypczak M. Epigenetic Changes Affecting the Development of Hepatocellular Carcinoma. Cancers (Basel). 2021; 13.
[13]Hlady RA, Zhao X, Pan X, et al. Genome-wide discovery and validation of diagnostic DNA methylation-based biomarkers for hepatocellular cancer detection in circulating cell free DNA. Theranostics. 2019; 9: 7239-7250.
[14]Long J, Chen P, Lin J, et al. DNA methylation-driven genes for constructing diagnostic, prognostic, and recurrence models for hepatocellular carcinoma. Theranostics. 2019; 9: 7251-7267.
[15]Zhao P, Malik S, Xing S. Epigenetic Mechanisms Involved in HCV-Induced Hepatocellular Carcinoma (HCC). Front Oncol. 2021; 11: 677926.
[16]Frederick RM, 2nd, Brandt J, Sheyn A. Drug-induced sleep endoscopy effect on intraoperative decision making in pediatric sleep surgery: A 2-year follow up. Laryngoscope Investig Otolaryngol. 2022; 7: 2112-2118.
[17]Xu Q, Hu Y, Chen S, et al. Immunological Significance of Prognostic DNA Methylation Sites in Hepatocellular Carcinoma. Front Mol Biosci. 2021; 8: 683240.
[18]Cheng J, Wei D, Ji Y, et al. Integrative analysis of DNA methylation and gene expression reveals hepatocellular carcinoma-specific diagnostic biomarkers. Genome Med. 2018; 10: 42.
[19]Li GX, Ding ZY, Wang YW, et al. Integrative analysis of DNA methylation and gene expression identify a six epigenetic driver signature for predicting prognosis in hepatocellular carcinoma. J Cell Physiol. 2019; 234: 11942-11950.
[20]Li G, Xu W, Zhang L, et al. Development and validation of a CIMP-associated prognostic model for hepatocellular carcinoma. EBioMedicine. 2019; 47: 128-141.
Copyright © 2025 Tongyu Liu, Chao Guo
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License
